Assessment of γδ T-cell therapies in humanized mice

Background

Current therapeutic approaches involving γδ T cells include adoptive cell transfer, in vivo stimulation and combined therapies. While preliminary results are promising, investigation of such therapies in preclinical models is challenging, because γδ T cells are not developed at satisfactory levels in most of the humanized mouse models. Here we describe the presence and functionality of γδ T cells in BRGSF (BALB/c Rag2^-/-, IL2Rγ^-/-, SIRPα^NOD and Flt3^-/-), a highly immunodeficient mouse featuring reduced murine myeloid cells. BRGSF mice reconstituted with human cord blood CD34⁺ cells (BRGSF-HIS) develop functional lymphoid and myeloid compartments. This engraftment is stable over a yearand mice do not develop GvHD.